skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Milatuzumab (Code C66983)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Milatuzumab

Definition: A humanized monoclonal antibody directed against human CD74 with potential antineoplastic activity. Milatuzumab specifically binds to CD74 on CD74-positive cells. Although the exact mechanism through which this agent induces apoptosis is unknown, it may involve antibody-dependent cellular cytotoxicity (ADCC) or complement-mediated cytotoxicity (CMC). Alternatively, as CD74 is the cellular receptor for the cytokine migration-inhibitory factor (MIF), the cytotoxicity of this agent may be related to inhibition of CD74 activation by MIF. CD74, an integral membrane protein that functions as an MHC class II chaperone, may also be an accessory-signaling molecule; activation of CD74 may initiate cell survival mechanisms involving induction of a signaling cascade resulting in NFkB activation, entry of stimulated cells into the S phase of the cell cycle, elevation of DNA synthesis, cell division, and augmented expression of Bcl-xL.

NCI-GLOSS Definition: A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. hLL1 is a type of monoclonal antibody.

Display Name: Milatuzumab

Label: Milatuzumab

NCI Thesaurus Code: C66983 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2716103  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Humanized Anti-CD74 Monoclonal Antibody hLL1
Monoclonal Antibody hLL1

External Source Codes: 
CAS Registry Number 899796-83-9 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 534127
PDQ Open Trial Search ID 534127 (check for NCI PDQ open clinical trial info)
UMLS CUI C2716103

Other Properties:
     Name Value (qualifiers indented underneath)
code C66983
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Milatuzumab
Legacy_Concept_Name Monoclonal_Antibody_hLL1
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom